A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.


The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.

DOI: 10.1038/nature11283

4 Figures and Tables

Showing 1-10 of 23 references

Alzheimer’s disease and frontotemporal dementia mutation database

  • M. Cruts
  • 2012

Alzheimer disease with distinctive features

  • Giaccone, G. et al. Neuropathology of the recessive A673V APPmutation
  • 2010

occurrence, determinants, and strategies toward intervention

  • C. Qiu, M. Kivipelto, von Strauss, E. Epidemiology of Alzheimer’s disease
  • 2009
Showing 1-10 of 265 extracted citations
Citations per Year

5,212 Citations

Semantic Scholar estimates that this publication has received between 3,737 and 7,042 citations based on the available data.

See our FAQ for additional information.